The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s glycopeptide antibiotics market report forecasts the glycopeptide antibiotics market size to grow to $4.43 Billion by 2027, with a CAGR (compound annual growth rate) of more than 7%.

Learn More On The Glycopeptide Antibiotics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Glycopeptide Antibiotics Market Size Forecast
The global glycopeptide antibiotics market is expected to grow from $3.05 billion in 2022 to $3.29 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global glycopeptide antibiotics market size is expected to grow to $4.43 billion in 2027 at a CAGR of 7.7%.

North America held the largest glycopeptide antibiotics market share.

Key Glycopeptide Antibiotics Market Driver ­– Rise In Number Of Cancer And Infectious Disease Cases
According to the American Cancer Society, a non-profit health organisation located in the United States dedicated to cancer eradication, the United States will have 1.9 million new cancer cases and 609,360 cancer deaths in 2022, for a total of 1,670 deaths each day. As a result, increased cancer and infectious illness instances will propel the glycopeptide antibiotics market forward.

Request for A Sample Of The Global Glycopeptide Antibiotics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp

Key Glycopeptide Antibiotics Market Trend – Product Innovation
To increase their market position, major businesses in the glycopeptide antibiotics market are focusing on producing innovative medicines. As an example, Leiden institute, a research institute in the Netherlands, found novel vancomycin variations in October 2022. To develop the new variant antibiotic vancomycin, a group of molecules was linked to the structure of an existing vancomycin molecule. When compared to commercially used polymyxin antibiotics, the novel vancomycin version is up to a thousand times more active against gram-positive bacteria than the original vancomycin and has lesser nephrotoxicity. This was developed to address the issue that vancomycin is only effective against gram-positive strains and cannot cross the outer membrane (OM) of gram-negative bacteria.

Glycopeptide Antibiotics Market Segment
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Glycopeptide Antibiotics Market Major Players and Strategies
Major players in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Melinta Therapeutics Inc., Cumberland Pharmaceuticals Inc., Theravance Biopharma Inc., Janssen Global, Bristol-Myers Squibb Company, GSK Plc., Allergan Plc., Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Lytix Biopharma, Alvogen, Eli Lilly and Company, and Bayer AG.

ANI Pharmaceuticals Inc, a US-based pharmaceutical manufacturing business that makes and markets both branded and generic prescription drugs, paid $163.5 million for Novitium Pharma in November 2021. ANI Pharmaceuticals Inc expands its well-established generics business by enhancing development skills and focusing more on specialised markets as a result of this purchase. Novitium Pharma is a new generic pharmaceutical firm established in the United States that manufactures generic medications.

The Glycopeptide Antibiotics Global Market Report 2023 covers regional data on glycopeptide antibiotics market size, glycopeptide antibiotics market trends and drivers, opportunities, strategies, and glycopeptide antibiotics market competitor analysis. The countries covered in the glycopeptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Glycopeptide antibiotics are a class of antibiotics that impede bacterial cell wall development by including a glycosylated cyclic or polycyclic non-ribosomal peptide. They were discovered first in plant and soil microorganisms.

View More Reports Related To The Glycopeptide Antibiotics Market –
Nutritional Feed Additives Global Market Report 2023
Anticoagulants Global Market Report 2023
Food Encapsulation Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: